- $32.96bn
- $38.43bn
- $9.84bn
- 89
- 44
- 60
- 70
Annual income statement for Biogen, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 14,378 | 13,445 | 10,982 | 10,173 | 9,836 |
Cost of Revenue | |||||
Gross Profit | 12,475 | 11,666 | 9,040 | 8,231 | 7,427 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 7,335 | 8,895 | 8,141 | 6,101 | 8,223 |
Operating Profit | 7,043 | 4,550 | 2,841 | 4,072 | 1,612 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 7,126 | 5,048 | 1,745 | 3,592 | 1,297 |
Provision for Income Taxes | |||||
Net Income After Taxes | 5,968 | 4,055 | 1,693 | 2,959 | 1,162 |
Minority Interest | |||||
Equity in Affiliates | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 5,889 | 4,001 | 1,556 | 3,047 | 1,161 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 5,889 | 4,001 | 1,556 | 3,047 | 1,161 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 32.9 | 26 | 15.7 | 18 | 10.1 |